| Rapamycin is efficacious against primary effusion lymphoma (PEL) cell lines in vivo by inhibiting autocrine signaling SH Sin, D Roy, L Wang, MR Staudt, FD Fakhari, DD Patel, D Henry, ... Blood 109 (5), 2165-2173, 2007 | 194 | 2007 |
| Dual inhibition of PI3K and mTOR inhibits autocrine and paracrine proliferative loops in PI3K/Akt/mTOR-addicted lymphomas AP Bhatt, PM Bhende, SH Sin, D Roy, DP Dittmer, B Damania Blood, The Journal of the American Society of Hematology 115 (22), 4455-4463, 2010 | 172 | 2010 |
| Replication fork regression in repetitive DNAs N Fouche, S Özgür, D Roy, JD Griffith Nucleic acids research 34 (20), 6044-6050, 2006 | 122 | 2006 |
| Tumor suppressor genes FHIT and WWOX are deleted in primary effusion lymphoma (PEL) cell lines D Roy, SH Sin, B Damania, DP Dittmer Blood, The Journal of the American Society of Hematology 118 (7), e32-e39, 2011 | 104 | 2011 |
| mTOR inhibitors block Kaposi sarcoma growth by inhibiting essential autocrine growth factors and tumor angiogenesis D Roy, SH Sin, A Lucas, R Venkataramanan, L Wang, A Eason, ... Cancer research 73 (7), 2235-2246, 2013 | 84 | 2013 |
| Rapamycin with antiretroviral therapy in AIDS-associated Kaposi sarcoma: an AIDS Malignancy Consortium study SE Krown, D Roy, JY Lee, BJ Dezube, EG Reid, R Venkataramanan, ... JAIDS Journal of Acquired Immune Deficiency Syndromes 59 (5), 447-454, 2012 | 74 | 2012 |
| Maribavir inhibits Epstein-Barr virus transcription in addition to viral DNA replication FZ Wang, D Roy, E Gershburg, CB Whitehurst, DP Dittmer, JS Pagano Journal of virology 83 (23), 12108-12117, 2009 | 52 | 2009 |
| Vironome of Kaposi sarcoma associated herpesvirus-inflammatory cytokine syndrome in an AIDS patient reveals co-infection of human herpesvirus 8 and human herpesvirus 6A KM Tamburro, D Yang, J Poisson, Y Fedoriw, D Roy, A Lucas, SH Sin, ... Virology 433 (1), 220-225, 2012 | 47 | 2012 |
| Cell cycle features of C. elegans germline stem/progenitor cells vary temporally and spatially. HEJ Roy D, Michaelson D, Hochman T, Santella A, Bao Z, Goldberg JD Developmental Biology 409 (1), 261-71, 2016 | 41 | 2016 |
| Functional Interactions Between rsks-1/S6K, glp-1/Notch, and Regulators of Caenorhabditis elegans Fertility and Germline Stem Cell Maintenance D Roy, DJ Kahler, C Yun, EJA Hubbard G3: Genes, Genomes, Genetics 8 (10), 3293-3309, 2018 | 38 | 2018 |
| Phosphatase and tensin homolog on chromosome 10 is phosphorylated in primary effusion lymphoma and Kaposi's sarcoma D Roy, DP Dittmer The American journal of pathology 179 (4), 2108-2119, 2011 | 27 | 2011 |
| Epstein–Barr virus microRNAs and lung cancer J Koshiol, ML Gulley, Y Zhao, M Rubagotti, FM Marincola, M Rotunno, ... British journal of cancer 105 (2), 320-326, 2011 | 26 | 2011 |
| Nuclear factor kappa B pathway associated biomarkers in AIDS defining malignancies JC Ramos, SH Sin, MR Staudt, D Roy, W Vahrson, BJ Dezube, ... International journal of cancer 130 (11), 2728-2733, 2012 | 18 | 2012 |
| Functional interactions between rsks-1/S6K, glp-1/Notch, and regulators of Caenorhabditis elegans fertility and germline stem cell maintenance. G3 (Bethesda) 8: 3293–3309 D Roy, DJ Kahler, C Yun, EJA Hubbard | 4 | 2018 |
| Increased chromosomal stability in cultures of ovarian tumours of low malignant potential compared to cystadenomas J Yu, D Roy, AD Brockmeyer, L Dubeau British journal of cancer 96 (12), 1908-1913, 2007 | 4 | 2007 |
| Real-world outcomes of lisocabtagene maraleucel (liso-cel) in patients (pt) with Richter transformation (RT) from the Center for International Blood and Marrow Transplant … AM Winter, S Bharadwaj, AF Herrera, C Iragavarapu, S Mirza, ... Journal of Clinical Oncology 42 (16_suppl), 7010-7010, 2024 | 2 | 2024 |
| Real-World (RW) Outcomes of Lisocabtagene Maraleucel (liso-cel) As Second-Line (2L) Therapy in Patients (pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL … MSO Bobillo, S Kambhampati, D Lee, BD Hunter, O Egini, K Patel, ... Blood 144, 470, 2024 | 1 | 2024 |
| Effectiveness and Safety Outcomes of Standard of Care (SOC) Lisocabtagene Maraleucel (liso-cel) in Patients (Pts) with Relapsed or Refractory (R/R) Transformed Large B-Cell … I Isufi, JL Crombie, M Frigault, C Andreadis, Y Lin, AS Mirza, S Kim, ... Transplantation and Cellular Therapy, Official Publication of the American …, 2025 | | 2025 |
| Outcomes of Standard of Care (SOC) Lisocabtagene Maraleucel (liso-cel) in Patients (Pts) with Relapsed or Refractory Large B-Cell Lymphoma (LBCL) and Secondary CNS (sCNS … S Ahmed, A Kallam, M Frigault, BD Hunter, SS Patel, D Bernasconi, S Kim, ... Transplantation and Cellular Therapy 31 (2), S227-S228, 2025 | | 2025 |
| Real-World (RW) Outcomes of Lisocabtagene Maraleucel (liso-cel) in Patients (pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL) and Secondary Central Nervous … S Ahmed, A Kallam, M Frigault, BD Hunter, SS Patel, D Bernasconi, S Kim, ... Blood 144, 472, 2024 | | 2024 |
Dirk DittmerChapel Hillmed.unc.edu üzerinde doğrulanmış e-posta adresine sahip
